Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Free Cash Flow Per Share for the year ending December 31, 2023: USD -2.20

Nyxoah S.A. Free Cash Flow Per Share is USD -2.20 for the year ending December 31, 2023, a -17.69% change year over year. Free cash flow per share is the free cash flow generated per share. Indicates investment potential based on cash flow generation.

Nyxoah S.A. Free Cash Flow Per Share for the year ending December 31, 2022 was USD -1.87, a -5.15% change year over year.
Nyxoah S.A. Free Cash Flow Per Share for the year ending December 31, 2021 was USD -1.78, a -48.83% change year over year.
Nyxoah S.A. Free Cash Flow Per Share for the year ending December 31, 2020 was USD -1.19, a -94.05% change year over year.
Nyxoah S.A. Free Cash Flow Per Share for the year ending December 31, 2019 was USD -0.62, a -36.77% change year over year.

Key data

Date	Free Cash Flow Per Share	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years